Treatment of live ex vivo cultured tumor cells harboring p.Gly12Val somatic mutations with anti-KRAS antibodies reduced inner plasma membrane localization of KRAS where it must tether to function (Figure 1F). This evidence concerns the gene KRAS and neoplasm.